Ethris has entered a strategic partnership with Thermo Fisher Scientific for providing completely integrated mRNA solution.

NHS England now offers the "Trojan horse" therapy, belantamab mafodotin (Blenrep) for patients with multiple myeloma.

Lynozyfic’s global sales are projected to reach $707 million by 2031.